# A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

> **NCT00927082** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 383 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a [Pegasys]

## Key facts

- **NCT ID:** NCT00927082
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2016-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927082, "A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00927082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*